John Houston

802 total citations
12 papers, 487 citations indexed

About

John Houston is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, John Houston has authored 12 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in John Houston's work include Protein Degradation and Inhibitors (9 papers), Prostate Cancer Treatment and Research (6 papers) and Ubiquitin and proteasome pathways (5 papers). John Houston is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Prostate Cancer Treatment and Research (6 papers) and Ubiquitin and proteasome pathways (5 papers). John Houston collaborates with scholars based in United States. John Houston's co-authors include Ryan R. Willard, Jennifer Pizzano, I Taylor, Mark Bookbinder, Lawrence B. Snyder, Andrew P. Crew, Craig M. Crews, Taavi K. Neklesa, Nicholas Vitale and Jennifer Macaluso and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

John Houston

10 papers receiving 478 citations

Peers

John Houston
Caterina Ferraro United States
BaoChau Le United States
Hoda Metwally United States
Samantha L. Savage United States
Andy Protter United States
Mylissa Borek United States
Marcos J. Ruiz United States
Véronique Mansat‐De Mas France
Melissa S. Hurd United States
Inchul You United States
Caterina Ferraro United States
John Houston
Citations per year, relative to John Houston John Houston (= 1×) peers Caterina Ferraro

Countries citing papers authored by John Houston

Since Specialization
Citations

This map shows the geographic impact of John Houston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Houston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Houston more than expected).

Fields of papers citing papers by John Houston

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Houston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Houston. The network helps show where John Houston may publish in the future.

Co-authorship network of co-authors of John Houston

This figure shows the co-authorship network connecting the top 25 collaborators of John Houston. A scholar is included among the top collaborators of John Houston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Houston. John Houston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Snyder, Lawrence B., Taavi K. Neklesa, Ryan R. Willard, et al.. (2024). Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. Molecular Cancer Therapeutics. 24(4). 511–522. 24 indexed citations
2.
Snyder, Larry, Taavi K. Neklesa, Xin Chen, et al.. (2023). Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 83(7_Supplement). ND03–ND03. 12 indexed citations
3.
Snyder, Lawrence B., John J. Flanagan, Yimin Qian, et al.. (2021). Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Research. 81(13_Supplement). 44–44. 74 indexed citations
4.
Snyder, Lawrence B., Taavi K. Neklesa, Xin Chen, et al.. (2021). Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 81(13_Supplement). 43–43. 49 indexed citations
5.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2019). ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). 259–259. 153 indexed citations
6.
Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2019). Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Research. 79(4_Supplement). P5–4. 106 indexed citations
7.
Cacace, Angela, John J. Flanagan, Michael Berlin, et al.. (2019). O5‐04‐05: A NEW THERAPEUTIC STRATEGY FOR TAUOPATHIES: DISCOVERY OF HIGHLY POTENT BRAIN PENETRANT PROTACTM DEGRADER MOLECULES THAT TARGET PATHOLOGIC TAU PROTEIN SPECIES. Alzheimer s & Dementia. 15(7S_Part_31). 2 indexed citations
8.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 381–381. 14 indexed citations
9.
Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2018). Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer. Cancer Research. 78(4_Supplement). P4–4. 2 indexed citations
10.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer. Cancer Research. 78(13_Supplement). 5236–5236. 50 indexed citations
11.
Houston, John. (1962). TEMPORAL PATTERNS IN A LA RECHERCHE DU TEMPS PERDU. French Studies. 16(1). 33–44. 1 indexed citations
12.
Houston, John. (1962). Temporal Patterns in A la Recherche du Temps Perdu. French Studies. 16(1). 33–44.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caterina Ferraro Breakdown of academic impact, for papers by BaoChau Le Breakdown of academic impact, for papers by Hoda Metwally Breakdown of academic impact, for papers by Samantha L. Savage Breakdown of academic impact, for papers by Andy Protter Breakdown of academic impact, for papers by Mylissa Borek Breakdown of academic impact, for papers by Marcos J. Ruiz Breakdown of academic impact, for papers by Véronique Mansat‐De Mas Breakdown of academic impact, for papers by Melissa S. Hurd Breakdown of academic impact, for papers by Inchul You
Rankless by CCL
2026